Neos Therapeutics seeks FDA approval for oral ADHD drug; Hospira snags 6 months exlusivity for pediatric intensive care injection;

> Neos Therapeutics filed with the FDA for approval of an extended-release amphetamine for the once-daily oral treatment for ADHD, the first of its kind. The NDA is targeted for completion by October. Release

> The FDA granted Hospira 6 months of pediatric market exclusivity for its Precedex injection, a sedative for patients in an intensive-care environment. Story

> A researcher at UMass Lowell is developing a drug-delivery method combined with an imaging agent that allows for the targeted treatment of breast cancer in HER2-positive women. The National Institutes of Health contributed more than $725,000 to the project. Release

> Vaccine developer Prokarium and the University of Birmingham's Institute of Microbiology pulled in a $600,000 grant to help develop an oral vaccine delivery platform, Vaxonella. Release

> Regulatory entities in Europe approved ThromboGenics' Jetrea, which is a one-time, single intravitreal injection for the breakdown of protein fibers in the treatment of vitreomacular traction. Article